Antibody Engineering & Optimization

AI-guided antibody optimization pipeline from preclinical lead to clinical candidate. Covers sequence humanization, structure modeling, affinity optimization, developability assessment, immunogenicity prediction, and manufacturing feasibility.

KEY PRINCIPLES:

• Report-first approach - Create optimization report before analysis

• Evidence-graded humanization - Score based on germline alignment and framework retention

• Developability-focused - Assess aggregation, stability, PTMs, immunogenicity

• Structure-guided - Use AlphaFold/PDB structures for CDR analysis

• Clinical precedent - Reference approved antibodies for validation

• Quantitative scoring - Developability score (0-100) combining multiple factors

• English-first queries - Always use English terms in tool calls, even if user writes in another language. Respond in user's language

When to Use

Apply when user asks:

• "Humanize this mouse antibody sequence"

• "Optimize antibody affinity for [target]"

• "Assess developability of this antibody"

• "Predict immunogenicity risk for [sequence]"

• "Engineer bispecific antibody against [targets]"

• "Reduce aggregation in antibody formulation"

• "Design pH-dependent binding antibody"

• "Analyze CDR sequences and suggest mutations"

Critical Workflow Requirements

1. Report-First Approach (MANDATORY)

Create the report file FIRST:

• File name: antibody_optimization_report.md

• Initialize with section headers

• Add placeholder: [Analyzing...]

Progressively update as analysis completes

Output separate files:

• optimized_sequences.fasta

• All optimized variants

• humanization_comparison.csv

• Before/after comparison

• developability_assessment.csv

• Detailed scores

2. Documentation Standards (MANDATORY)

Every optimization MUST include:

Optimized Variant: VH_Humanized_v1

Original Sequence: EVQLVESGGGLVQPGG... (mouse) Humanized Sequence: EVQLVQSGAEVKKPGA... (human framework) Humanization Score: 87% human framework CDR Preservation: 100% (all CDR residues retained)

Metrics:

Source: IMGT germline analysis, IEDB predictions

Phase 0: Tool Verification

Required Tools

Tool Purpose Category

IMGT_search_genes

Germline gene identification Humanization

IMGT_get_sequence

Human framework sequences Humanization

SAbDab_search_structures

Antibody structure precedents Structure

TheraSAbDab_search_by_target

Clinical antibody benchmarks Validation

AlphaFold_get_prediction

Structure modeling Structure

iedb_search_epitopes

Epitope identification Immunogenicity

iedb_search_bcell

B-cell epitope prediction Immunogenicity

UniProt_get_protein_by_accession

Target antigen information Target

STRING_get_interactions

Protein interaction network Bispecifics

PubMed_search

Literature precedents Validation

Workflow Overview

Phase 1: Input Analysis & Characterization ├── Sequence annotation (CDRs, framework) ├── Species identification ├── Target antigen identification ├── Clinical precedent search └── OUTPUT: Input characterization ↓ Phase 2: Humanization Strategy ├── Germline gene alignment (IMGT) ├── Framework selection ├── CDR grafting design ├── Backmutation identification └── OUTPUT: Humanization plan ↓ Phase 3: Structure Modeling & Analysis ├── AlphaFold prediction ├── CDR conformation analysis ├── Epitope mapping ├── Interface analysis └── OUTPUT: Structural assessment ↓ Phase 4: Affinity Optimization ├── In silico mutation screening ├── CDR optimization strategies ├── Interface improvement └── OUTPUT: Affinity variants ↓ Phase 5: Developability Assessment ├── Aggregation propensity ├── PTM site identification ├── Stability prediction ├── Expression prediction └── OUTPUT: Developability score ↓ Phase 6: Immunogenicity Prediction ├── MHC-II epitope prediction (IEDB) ├── T-cell epitope risk ├── Aggregation-related immunogenicity └── OUTPUT: Immunogenicity risk score ↓ Phase 7: Manufacturing Feasibility ├── Expression level prediction ├── Purification considerations ├── Formulation stability └── OUTPUT: Manufacturing assessment ↓ Phase 8: Final Report & Recommendations ├── Ranked variant list ├── Experimental validation plan ├── Next steps └── OUTPUT: Comprehensive report

Phase 1: Input Analysis & Characterization

1.1 Sequence Annotation

def annotate_antibody_sequence(sequence): """Annotate antibody sequence with CDRs and framework regions."""

# Use IMGT numbering scheme (standard for antibodies)
# CDR definitions (IMGT):
# CDR-H1: 27-38, CDR-H2: 56-65, CDR-H3: 105-117
# CDR-L1: 27-38, CDR-L2: 56-65, CDR-L3: 105-117

annotation = {
    'sequence': sequence,
    'length': len(sequence),
    'regions': {
        'FR1': sequence[0:26],
        'CDR1': sequence[26:38],
        'FR2': sequence[38:55],
        'CDR2': sequence[55:65],
        'FR3': sequence[65:104],
        'CDR3': sequence[104:117],
        'FR4': sequence[117:]
    }
}

return annotation

1.2 Species & Germline Identification

def identify_germline(tu, vh_sequence, vl_sequence): """Identify germline genes for VH and VL chains using IMGT."""

# Search for human germline genes
vh_germlines = tu.tools.IMGT_search_genes(
    gene_type="IGHV",
    species="Homo sapiens"
)

vl_germlines = tu.tools.IMGT_search_genes(
    gene_type="IGKV",  # or IGLV for lambda
    species="Homo sapiens"
)

# Get sequences for top matches
# Calculate identity % for each germline
# Return closest matches

return {
    'vh_germline': 'IGHV1-69*01',
    'vh_identity': 87.2,
    'vl_germline': 'IGKV1-39*01',
    'vl_identity': 89.5
}

1.3 Clinical Precedent Search

def search_clinical_precedents(tu, target_antigen): """Find approved/clinical antibodies against same target."""

# Search Thera-SAbDab for clinical antibodies
therapeutics = tu.tools.TheraSAbDab_search_by_target(
    target=target_antigen
)

approved = [ab for ab in therapeutics if ab['phase'] == 'Approved']
clinical = [ab for ab in therapeutics if 'Phase' in ab['phase']]

return {
    'approved_count': len(approved),
    'clinical_count': len(clinical),
    'examples': approved[:3],
    'insights': extract_design_patterns(approved)
}

1.4 Output for Report

1. Input Characterization

1.1 Sequence Information

1.2 CDR Annotation (IMGT Numbering)

Heavy Chain:

• FR1: 1-26, CDR-H1: 27-38, FR2: 39-55, CDR-H2: 56-65, FR3: 66-104, CDR-H3: 105-117, FR4: 118-128

CDR Sequences:

1.3 Target Information

1.4 Clinical Precedents

Approved antibodies targeting PD-L1:

1. Atezolizumab (Tecentriq) - IgG1, approved 2016
2. Durvalumab (Imfinzi) - IgG1, approved 2017
3. Avelumab (Bavencio) - IgG1, approved 2017

Key insights: All approved anti-PD-L1 antibodies use human IgG1 scaffolds with effector function modifications.

Source: TheraSAbDab, UniProt

Phase 2: Humanization Strategy

2.1 Framework Selection

def select_human_framework(tu, mouse_sequence, cdr_sequences): """Select optimal human framework for CDR grafting."""

# Search IMGT for human germline genes
vh_genes = tu.tools.IMGT_search_genes(
    gene_type="IGHV",
    species="Homo sapiens"
)

# For each candidate framework:
# 1. Calculate sequence identity to mouse FR
# 2. Check CDR canonical class compatibility
# 3. Assess structural compatibility
# 4. Consider clinical precedents

candidates = []
for gene in vh_genes[:20]:  # Top 20 human germlines
    gene_seq = tu.tools.IMGT_get_sequence(
        accession=gene['accession'],
        format='fasta'
    )

    score = calculate_framework_score(
        mouse_fr=extract_framework(mouse_sequence),
        human_fr=extract_framework(gene_seq),
        cdr_compatibility=check_cdr_compatibility(cdr_sequences, gene_seq)
    )

    candidates.append({
        'germline': gene['name'],
        'identity': score['identity'],
        'cdr_compatibility': score['cdr_compatibility'],
        'clinical_use': count_clinical_uses(gene['name']),
        'overall_score': score['total']
    })

# Sort by overall score
return sorted(candidates, key=lambda x: x['overall_score'], reverse=True)

2.2 CDR Grafting Design

def design_cdr_grafting(mouse_sequence, human_framework, cdr_sequences): """Design CDR grafting with backmutation identification."""

# Graft mouse CDRs onto human framework
grafted_sequence = graft_cdrs(
    human_framework=human_framework,
    mouse_cdrs=cdr_sequences
)

# Identify Vernier zone residues (affect CDR conformation)
vernier_residues = [2, 27, 28, 29, 30, 47, 48, 67, 69, 71, 78, 93, 94]

# Identify potential backmutations
backmutations = []
for pos in vernier_residues:
    if mouse_sequence[pos] != human_framework[pos]:
        backmutations.append({
            'position': pos,
            'human_aa': human_framework[pos],
            'mouse_aa': mouse_sequence[pos],
            'reason': 'Vernier zone - may affect CDR conformation',
            'priority': 'High' if pos in [27, 29, 30, 48] else 'Medium'
        })

return {
    'grafted_sequence': grafted_sequence,
    'backmutations': backmutations,
    'humanness_score': calculate_humanness(grafted_sequence)
}

2.3 Humanization Scoring

def calculate_humanization_score(sequence, human_germline): """Calculate comprehensive humanization score."""

# Framework humanness (% identity to human germline)
fr_identity = calculate_framework_identity(sequence, human_germline)

# T-cell epitope content (lower is better)
tcell_epitope_count = predict_tcell_epitopes(sequence)

# Unusual residues in human context
unusual_residues = count_unusual_residues(sequence)

# Aggregation hotspots
aggregation_motifs = find_aggregation_motifs(sequence)

score = {
    'framework_humanness': fr_identity,  # 0-100%
    'cdr_preservation': 100,  # Always 100% initially
    'tcell_epitopes': tcell_epitope_count,
    'unusual_residues': unusual_residues,
    'aggregation_risk': len(aggregation_motifs),
    'overall_score': calculate_weighted_score(
        fr_identity, tcell_epitope_count, unusual_residues, aggregation_motifs
    )
}

return score

2.4 Output for Report

2. Humanization Strategy

2.1 Framework Selection

Selected Human Frameworks:

Rationale:

• IGHV1-69*01: Most frequently used human germline in therapeutic antibodies
• High sequence identity minimizes risk of affinity loss
• Excellent CDR canonical class compatibility
• Proven clinical track record

2.2 CDR Grafting Design

Grafting Strategy: Direct CDR transfer with Vernier zone optimization

2.3 Backmutation Analysis

Identified Vernier Zone Residues (may require backmutation):

Recommendation: Test versions with/without backmutations at positions 27 and 48

2.4 Humanized Sequences

Version 1: Full humanization (no backmutations)

VH_Humanized_v1 | 87% human framework EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGGIIPIFGTANY AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS

Version 2: With key backmutations (positions 27, 48)

VH_Humanized_v2 | 85% human framework + backmutations EVQLVQSGAEVKKPGASVKVSCKASGYAFTSYYMHWVRQAPGQGLEWMVGIIPIFGTANY AQKFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS

Humanization Metrics:

Source: IMGT germline database, CDR analysis

Phase 3: Structure Modeling & Analysis

3.1 AlphaFold Structure Prediction

def predict_antibody_structure(tu, vh_sequence, vl_sequence): """Predict antibody Fv structure using AlphaFold."""

# Combine VH and VL with linker
fv_sequence = vh_sequence + ":" + vl_sequence  # AlphaFold uses : for chain separator

# Predict structure
prediction = tu.tools.AlphaFold_get_prediction(
    sequence=fv_sequence,
    return_format='pdb'
)

# Extract pLDDT scores
plddt_scores = extract_plddt(prediction)

# Analyze by region
regions = {
    'VH_FR': np.mean([plddt_scores[i] for i in range(0, 26)]),
    'CDR_H1': np.mean([plddt_scores[i] for i in range(26, 38)]),
    'CDR_H2': np.mean([plddt_scores[i] for i in range(55, 65)]),
    'CDR_H3': np.mean([plddt_scores[i] for i in range(104, 117)]),
    'VL_FR': np.mean([plddt_scores[i] for i in range(len(vh_sequence), len(vh_sequence)+26)]),
    'CDR_L1': np.mean([plddt_scores[i] for i in range(len(vh_sequence)+26, len(vh_sequence)+38)]),
}

return {
    'structure': prediction,
    'mean_plddt': np.mean(plddt_scores),
    'regional_plddt': regions,
    'cdr_confidence': np.mean([regions['CDR_H1'], regions['CDR_H2'], regions['CDR_H3']])
}

3.2 CDR Conformation Analysis

def analyze_cdr_conformation(structure): """Analyze CDR loop conformations and canonical classes."""

# Extract CDR coordinates
cdr_coords = extract_cdr_regions(structure)

# Classify canonical structures
cdr_classes = {
    'CDR-H1': classify_canonical_structure(cdr_coords['H1']),
    'CDR-H2': classify_canonical_structure(cdr_coords['H2']),
    'CDR-H3': 'Non-canonical (14 aa)',  # Usually unique
    'CDR-L1': classify_canonical_structure(cdr_coords['L1']),
    'CDR-L2': classify_canonical_structure(cdr_coords['L2']),
    'CDR-L3': classify_canonical_structure(cdr_coords['L3'])
}

# Calculate RMSD to known canonical structures
rmsd_values = calculate_canonical_rmsd(cdr_coords, cdr_classes)

return {
    'classes': cdr_classes,
    'rmsd': rmsd_values,
    'confidence': assess_conformation_confidence(rmsd_values)
}

3.3 Epitope Mapping

def map_epitope(tu, target_protein, antibody_structure): """Identify epitope on target protein."""

# Get target structure or predict
target_info = tu.tools.UniProt_get_protein_by_accession(
    accession=target_protein
)

# Search for known epitopes
epitopes = tu.tools.iedb_search_epitopes(
    sequence_contains=target_protein,
    structure_type="Linear peptide",
    limit=20
)

# Search for structural antibody complexes
sabdab_results = tu.tools.SAbDab_search_structures(
    query=target_info['protein_name']
)

# Analyze binding interface
interface = {
    'epitope_candidates': epitopes,
    'structural_precedents': sabdab_results,
    'predicted_interface': predict_binding_interface(antibody_structure)
}

return interface

3.4 Output for Report

3. Structure Modeling & Analysis

3.1 AlphaFold Predictions

Structure Quality:

Regional Confidence (v2):

• Framework regions: 92.3 (very high)
• CDR-H1, H2, L1, L2: 87-91 (high)
• CDR-H3: 78.4 (moderate - expected for unique CDR-H3)
• VH-VL interface: 90.1 (high)

3.2 CDR Conformation Analysis

Canonical Classes (Humanized v2):

Assessment: All CDR conformations well-preserved in humanized variants. Low RMSD values indicate minimal structural perturbation from humanization.

3.3 Epitope Analysis

Known PD-L1 Epitopes (IEDB):

Predicted Binding Interface:

• Primary contact residues: CDR-H3 (70%), CDR-H1 (15%), CDR-H2 (10%)
• Secondary contacts: CDR-L3 (5%)
• Estimated buried surface area: 820 Ų

3.4 Structural Comparison

Superposition with Clinical Antibodies (SAbDab):

Source: AlphaFold, IEDB, SAbDab

Phase 4: Affinity Optimization

4.1 In Silico Mutation Screening

def design_affinity_variants(antibody_structure, target_structure): """Design affinity maturation variants using computational screening."""

# Identify interface residues
interface_residues = identify_interface_residues(
    antibody_structure,
    target_structure,
    distance_cutoff=4.5  # Angstroms
)

# Focus on CDR residues
cdr_interface = [res for res in interface_residues if is_cdr_residue(res)]

# Design mutations for each position
variants = []
for position in cdr_interface:
    # Try all amino acids except original
    for aa in 'ACDEFGHIKLMNPQRSTVWY':
        if aa != antibody_structure.sequence[position]:
            predicted_ddg = predict_binding_energy_change(
                structure=antibody_structure,
                mutation=f"{antibody_structure.sequence[position]}{position}{aa}"
            )

            if predicted_ddg < -0.5:  # Favorable change (more negative = better)
                variants.append({
                    'position': position,
                    'original': antibody_structure.sequence[position],
                    'mutant': aa,
                    'predicted_ddg': predicted_ddg,
                    'predicted_kd_fold': calculate_kd_change(predicted_ddg)
                })

# Rank by predicted improvement
return sorted(variants, key=lambda x: x['predicted_ddg'])

4.2 CDR Optimization Strategies

def cdr_optimization_strategies(cdr_sequence, cdr_name): """Identify CDR optimization strategies based on sequence and structure."""

strategies = []

# Strategy 1: Extend CDR for increased contact area
if len(cdr_sequence) < 12 and cdr_name == 'CDR-H3':
    strategies.append({
        'strategy': 'CDR-H3 extension',
        'rationale': 'Add 1-2 residues to increase contact surface',
        'expected_impact': '+2-5x affinity improvement',
        'examples': ['Extension with Gly-Tyr', 'Extension with Ser-Asp']
    })

# Strategy 2: Tyrosine enrichment
tyr_count = cdr_sequence.count('Y')
if tyr_count < 2:
    strategies.append({
        'strategy': 'Tyrosine enrichment',
        'rationale': 'Tyr provides pi-stacking and H-bonds',
        'expected_impact': '+2-3x affinity improvement',
        'targets': suggest_tyr_positions(cdr_sequence)
    })

# Strategy 3: Charged residue optimization
if 'PD' in cdr_sequence or 'EP' in cdr_sequence:
    strategies.append({
        'strategy': 'Salt bridge formation',
        'rationale': 'Add charged residues for electrostatic interactions',
        'expected_impact': '+1-2x affinity and pH sensitivity',
        'targets': identify_salt_bridge_opportunities(cdr_sequence)
    })

return strategies

4.3 Output for Report

4. Affinity Optimization

4.1 Current Affinity Assessment

Target: Single-digit nM affinity (KD < 5 nM)

4.2 Proposed Affinity Mutations

High-Priority Mutations (predicted >2x improvement):

Medium-Priority Mutations (predicted 1.5-2x improvement):

4.3 Combination Strategy

Recommended Testing Order:

1. Single mutants: H100aY, H52W, L91E (test individually)
2. Double mutants: H100aY+H52W, H100aY+L91E (best combinations)
3. Triple mutant: H100aY+H52W+L91E (if additivity observed)

Expected Outcome:

• Single mutants: KD 1.5-2.5 nM (3-7x improvement)
• Best double mutant: KD 0.7-1.2 nM (7-15x improvement)
• Triple mutant: KD 0.3-0.6 nM (15-30x improvement) if additive

4.4 CDR Optimization Strategies

Strategy 1: CDR-H3 Extension

• Current length: 14 aa
• Proposed: Add Gly-Tyr at C-terminus (16 aa total)
• Rationale: Fill gap in binding interface, Tyr provides pi-stacking
• Expected impact: +2-3x affinity

Strategy 2: Tyrosine Enrichment

• Current Tyr count: 3 in CDRs
• Target positions: H33, H52a, L96
• Rationale: Tyr provides both hydrophobic and H-bond contacts
• Expected impact: +2-4x affinity

Strategy 3: pH-Dependent Binding (Optional)

• For tumor-selective uptake
• Add His residues at interface: H100a, L91
• pKa ~6.0: Bind at pH 7.4, release at pH 6.0
• Expected impact: Tumor selectivity, faster recycling

Source: In silico modeling, structural analysis

Phase 5: Developability Assessment

5.1 Aggregation Propensity

def assess_aggregation(sequence): """Comprehensive aggregation risk assessment."""

# Identify aggregation-prone regions (APR)
aprs = find_aggregation_motifs(sequence)

# Hydrophobic patches on surface
hydrophobic_patches = identify_surface_hydrophobic(sequence)

# Charge patches (extreme pI regions)
charge_patches = identify_charge_clusters(sequence)

# Sequence-based prediction scores
tango_score = predict_tango_score(sequence)  # Beta-aggregation
aggrescan_score = predict_aggrescan(sequence)  # General aggregation

# Isoelectric point
pi = calculate_isoelectric_point(sequence)

return {
    'apr_count': len(aprs),
    'apr_regions': aprs,
    'hydrophobic_patches': hydrophobic_patches,
    'charge_patches': charge_patches,
    'tango_score': tango_score,
    'aggrescan_score': aggrescan_score,
    'pi': pi,
    'overall_risk': categorize_risk(tango_score, aggrescan_score, len(aprs))
}

5.2 PTM Site Identification

def identify_ptm_sites(sequence): """Identify post-translational modification liability sites."""

ptm_sites = {
    'deamidation': [],
    'isomerization': [],
    'oxidation': [],
    'glycosylation': []
}

# Deamidation: Asn followed by Gly or Ser (NG, NS motifs)
for i, aa in enumerate(sequence[:-1]):
    if aa == 'N' and sequence[i+1] in ['G', 'S']:
        ptm_sites['deamidation'].append({
            'position': i,
            'motif': sequence[i:i+2],
            'risk': 'High' if sequence[i+1] == 'G' else 'Medium',
            'region': identify_region(i)
        })

# Isomerization: Asp followed by Gly or Ser (DG, DS motifs)
for i, aa in enumerate(sequence[:-1]):
    if aa == 'D' and sequence[i+1] in ['G', 'S']:
        ptm_sites['isomerization'].append({
            'position': i,
            'motif': sequence[i:i+2],
            'risk': 'High',
            'region': identify_region(i)
        })

# Oxidation: Met and Trp residues
for i, aa in enumerate(sequence):
    if aa in ['M', 'W']:
        ptm_sites['oxidation'].append({
            'position': i,
            'residue': aa,
            'risk': 'Medium',
            'region': identify_region(i)
        })

# N-glycosylation: N-X-S/T motif (X != P)
for i in range(len(sequence)-2):
    if sequence[i] == 'N' and sequence[i+1] != 'P' and sequence[i+2] in ['S', 'T']:
        ptm_sites['glycosylation'].append({
            'position': i,
            'motif': sequence[i:i+3],
            'region': identify_region(i)
        })

return ptm_sites

5.3 Developability Scoring

def calculate_developability_score(sequence, structure): """Calculate comprehensive developability score (0-100)."""

# Component scores
aggregation = assess_aggregation(sequence)
ptm = identify_ptm_sites(sequence)
stability = predict_thermal_stability(structure)
expression = predict_expression_level(sequence)
solubility = predict_solubility(sequence)

# Scoring rubric (0-100 for each)
scores = {
    'aggregation': score_aggregation(aggregation),  # 100 = low risk
    'ptm_liability': score_ptm_risk(ptm),  # 100 = no PTM sites
    'stability': score_stability(stability),  # 100 = Tm > 70°C
    'expression': score_expression(expression),  # 100 = >1 g/L
    'solubility': score_solubility(solubility)  # 100 = >100 mg/mL
}

# Weighted average
weights = {
    'aggregation': 0.30,  # Most critical
    'ptm_liability': 0.25,
    'stability': 0.20,
    'expression': 0.15,
    'solubility': 0.10
}

overall = sum(scores[k] * weights[k] for k in scores.keys())

return {
    'component_scores': scores,
    'overall_score': overall,
    'tier': categorize_developability(overall)
}

5.4 Output for Report

5. Developability Assessment

5.1 Overall Developability Score

Scoring: 0-100 scale (higher is better), Tiers: T1 (>75), T2 (60-75), T3 (<60)

5.2 Aggregation Analysis

Aggregation-Prone Regions (APR) in VH:

Overall Aggregation Risk:

• VH: Low (TANGO: 15, AGGRESCAN: -12)
• VL: Very Low (TANGO: 8, AGGRESCAN: -18)
• pI: VH 7.2, VL 5.8 (favorable for purification)

Recommendations:

• Formulate at pH 6.0-6.5 (below pI of VH)
• Add arginine-glutamate (20-50 mM) to reduce aggregation
• Target concentration: >100 mg/mL achievable

5.3 PTM Liability Sites

High-Risk PTM Sites (require mitigation):

Medium-Risk Sites:

• H89: Trp (oxidation) - Monitor but likely stable in framework
• L97: Asn (deamidation, NS motif) - Low risk in CDR-L3

Mitigation Priority:

1. H54-55 (NG → NQ): Removes high-risk deamidation, retains H-bond capability
2. H84-85 (DS → ES): Removes isomerization, maintains charge
3. L28 (M → L): Reduces oxidation risk, maintains hydrophobicity

Expected Impact: Mitigation improves PTM score from 72 → 92

5.4 Stability Predictions

Thermal Stability:

Target: Tm >70°C, Tonset >65°C for long-term stability

Stability Optimization:

• Framework humanization improved Tm by +3°C
• Removal of destabilizing motifs: +2°C
• Further optimization possible: Proline introduction in loops

5.5 Expression & Manufacturing

Expression Prediction (CHO cells):

Manufacturing Considerations:

• No unusual codons → Good for CHO expression
• No free cysteines → No misfolding risk
• Neutral pI → Easy purification by ion exchange
• Low aggregation → High formulation concentration possible

Predicted Manufacturing Profile:

• Expression: 2.0 g/L (CHO fed-batch)
• Purification yield: 75-80%
• Final formulation: >150 mg/mL achievable
• Shelf life: >2 years at 4°C (estimated)

Source: In silico predictions, sequence analysis

Phase 6: Immunogenicity Prediction

6.1 T-Cell Epitope Prediction

def predict_tcell_epitopes(tu, sequence): """Predict T-cell epitopes using IEDB tools."""

# MHC-II binding prediction (immunogenicity risk)
# Query IEDB for predicted epitopes
predicted_epitopes = []

# Scan sequence with 9-mer sliding window
for i in range(len(sequence) - 8):
    peptide = sequence[i:i+9]

    # Search IEDB for similar epitopes
    iedb_results = tu.tools.iedb_search_epitopes(
        sequence_contains=peptide[:5],  # Core sequence
        limit=10
    )

    # If found in IEDB → higher risk
    if len(iedb_results) > 0:
        predicted_epitopes.append({
            'position': i,
            'peptide': peptide,
            'risk': 'High',
            'evidence': f"{len(iedb_results)} similar epitopes in IEDB"
        })

# Score overall immunogenicity risk
risk_score = calculate_immunogenicity_risk(predicted_epitopes, sequence)

return {
    'epitope_count': len(predicted_epitopes),
    'high_risk_epitopes': [e for e in predicted_epitopes if e['risk'] == 'High'],
    'risk_score': risk_score,
    'recommendation': recommend_deimmunization(predicted_epitopes)
}

6.2 Immunogenicity Risk Scoring

def calculate_immunogenicity_risk(epitopes, sequence): """Calculate comprehensive immunogenicity risk score."""

# Component 1: T-cell epitope count (IEDB-based)
tcell_score = len(epitopes) * 10  # Each epitope adds 10 points

# Component 2: Non-human residues in framework
non_human_residues = count_non_human_residues(sequence)
non_human_score = non_human_residues * 5

# Component 3: Aggregation-related immunogenicity
aggregation_score = assess_aggregation(sequence)['overall_risk'] * 20

# Total risk (0-100, lower is better)
total_risk = min(100, tcell_score + non_human_score + aggregation_score)

return {
    'tcell_risk': tcell_score,
    'non_human_risk': non_human_score,
    'aggregation_risk': aggregation_score,
    'total_risk': total_risk,
    'category': 'Low' if total_risk < 30 else 'Medium' if total_risk < 60 else 'High'
}

6.3 Output for Report

6. Immunogenicity Prediction

6.1 T-Cell Epitope Analysis

Predicted MHC-II Binding Epitopes (IEDB):

High-Risk Epitope Details:

• VH 78-86 (TDTSTSTA): Contains mouse-derived residues T84, S85
  • Found in 5 immunogenic peptides in IEDB
  • Recommendation: Backmutate to human consensus (TSTSSAYL)

6.2 Immunogenicity Risk Score

Risk Scoring: 0-100 (lower is better)

• Low risk: <30 (clinical candidate ready)
• Medium risk: 30-60 (acceptable with monitoring)
• High risk: >60 (requires optimization)

6.3 Deimmunization Strategy

Recommended Mutations (to achieve low risk):

Expected Outcome:

• Deimmunization reduces risk score: 53 → 32 (Low)
• T-cell epitopes reduced: 4 → 2
• Maintains CDR sequences (no affinity impact)

6.4 Clinical Precedent Comparison

Approved Antibodies - Immunogenicity Rates:

Our Candidate:

• Humanization: 85-87% (similar to trastuzumab)
• Predicted ADA risk: 10-15% (after deimmunization)
• Acceptable for clinical development

Source: IEDB, TheraSAbDab, clinical trial data

Phase 7: Manufacturing Feasibility

7.1 Expression Optimization

def assess_manufacturing_feasibility(sequence): """Assess manufacturing and CMC feasibility."""

# Codon optimization for CHO
cho_optimized = optimize_codons(sequence, host='CHO')
rare_codons = count_rare_codons(sequence, host='CHO')

# Signal peptide design
signal_peptide = design_signal_peptide(sequence)

# Purification considerations
purification = {
    'protein_a_binding': check_protein_a_binding(sequence),
    'ion_exchange': suggest_ion_exchange_conditions(sequence),
    'hydrophobic': suggest_hic_conditions(sequence)
}

# Formulation
formulation = {
    'target_concentration': predict_max_concentration(sequence),
    'buffer': suggest_buffer_conditions(sequence),
    'stabilizers': suggest_stabilizers(sequence),
    'shelf_life': predict_shelf_life(sequence)
}

return {
    'expression': {'cho_optimized': cho_optimized, 'rare_codons': rare_codons},
    'purification': purification,
    'formulation': formulation
}

7.2 Output for Report

7. Manufacturing Feasibility

7.1 Expression Assessment

Expression System: CHO (Chinese Hamster Ovary) cells

Recommendations:

• Use standard CHO expression system (CHO-K1 or CHO-S)
• Express as full IgG1 (not Fab) for Protein A purification
• Standard fed-batch process (no special requirements)

7.2 Purification Strategy

Recommended 3-Step Purification:

Overall Process Yield: 75-80% (from clarified harvest to final product)

Purification Conditions:

• Protein A: Standard pH 3.5 elution
• Cation exchange: pH 5.0-5.5 binding, salt gradient elution
• No special requirements (standard IgG process)

7.3 Formulation Development

Recommended Formulation:

Formulation Characteristics:

• Viscosity: <15 cP (suitable for SC injection)
• Osmolality: 300 mOsm/kg (isotonic)
• Stability: >2 years at 2-8°C (predicted)
• Freeze/thaw: Stable for 5 cycles

Alternative Formulations (if needed):

• Lower concentration (100 mg/mL) for IV delivery
• Add arginine-glutamate (50 mM) if aggregation observed
• Trehalose (5%) as alternative stabilizer

7.4 Analytical Characterization

Required Assays (ICH guidelines):

7.5 CMC Timeline & Costs

Estimated Development Timeline:

Manufacturing Scale:

• Phase 1: 5-10g (small scale, 50L bioreactor)
• Phase 2: 50-100g (pilot scale, 200L)
• Phase 3: 500g-1kg (commercial scale, 2000L)

7.6 Risk Assessment

Manufacturing Risks:

Overall Manufacturing Risk: Low (standard IgG process)

Source: CMC assessment, manufacturing predictions

Phase 8: Final Report & Recommendations

Report Template

Antibody Optimization Report: [ANTIBODY_NAME]

Generated: [Date] | Target: [Target Antigen] | Status: Complete

Executive Summary

[Summary of optimization strategy, key improvements, and recommendations...]

Top Candidate: [Variant name]

• Humanization: 87% (from 62%)
• Affinity: 1.2 nM (7x improvement)
• Developability score: 82/100 (Tier 1)
• Immunogenicity: Low risk
• Manufacturing: Standard process

Recommendation: Advance to preclinical development

1. Input Characterization

[Section from Phase 1...]

2. Humanization Strategy

[Section from Phase 2...]

3. Structure Modeling & Analysis

[Section from Phase 3...]

4. Affinity Optimization

[Section from Phase 4...]

5. Developability Assessment

[Section from Phase 5...]

6. Immunogenicity Prediction

[Section from Phase 6...]

7. Manufacturing Feasibility

[Section from Phase 7...]

8. Final Recommendations

8.1 Recommended Candidate

Variant: VH_Humanized_Affinity_Optimized_v3

Sequence:

VH_v3 | Humanized 87%, Affinity optimized, Deimmunized EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMWGIIPIFGTANY AQKFQGRVTMTTDTSTSSAYMELRSLRSDDTAVYYCARARDDGSYSPFDYWGQGTLVTVSS

VL_v3 | Humanized 90% DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPS RFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIK

8.2 Key Improvements

8.3 Experimental Validation Plan

Phase 1: In Vitro Characterization (3-4 months)

Phase 2: Lead Optimization (2-3 months)

• Test backup variants if needed
• Formulation development
• Scale-up to 100mg

Phase 3: Preclinical Studies (6-12 months)

• In vivo efficacy (tumor models)
• PK/PD studies
• Toxicology (GLP)

8.4 Alternative Variants (Backup)

8.5 Intellectual Property Considerations

FTO Analysis Required:

• Check existing patents on anti-[target] antibodies
• CDR sequence novelty assessment
• Humanization method IP landscape

Patentability:

• Novel CDR-H3 sequence (14 aa, unique)
• Specific humanization with affinity improvement
• Combination of mutations (H100aY+H52W+L91E)

8.6 Next Steps

Immediate (Month 1-3):

1. Synthesize genes for VH_v3, VL_v3, and 2 backups
2. Express in CHO cells (transient and stable)
3. Purify and characterize (affinity, stability, aggregation)
4. Confirm developability predictions

Short-term (Month 4-6):

1. Develop stable CHO cell line (top candidate)
2. Scale up to 500mg for in vivo studies
3. Formulation development and stability studies
4. Initiate in vivo efficacy studies

Long-term (Month 7-24):

1. GMP manufacturing readiness
2. IND-enabling studies (tox, CMC)
3. File IND
4. Phase 1 clinical trial

9. Data Sources & Tools Used

Evidence Grading System

Tier Symbol Criteria

T1 ★★★ Humanness >85%, KD <2 nM, Developability >75, Low immunogenicity

T2 ★★☆ Humanness 70-85%, KD 2-10 nM, Developability 60-75, Medium immunogenicity

T3 ★☆☆ Humanness <70%, KD >10 nM, Developability <60, or High immunogenicity

T4 ☆☆☆ Failed validation or major liabilities

Completeness Checklist

Phase 1: Input Analysis

• Sequence annotated (CDRs, frameworks)

• Species identified

• Target antigen characterized

• Clinical precedents identified

Phase 2: Humanization

• Germline genes identified (IMGT)

• Framework selected

• CDR grafting designed

• Backmutations analyzed

• ≥2 humanized variants designed

Phase 3: Structure

• AlphaFold structure predicted

• CDR conformations analyzed

• Epitope mapped

• Structural quality assessed

Phase 4: Affinity

• Current affinity estimated

• Affinity mutations proposed

• CDR optimization strategies identified

• Testing plan outlined

Phase 5: Developability

• Aggregation assessed

• PTM sites identified

• Stability predicted

• Expression predicted

• Overall score calculated (0-100)

Phase 6: Immunogenicity

• T-cell epitopes predicted (IEDB)

• Immunogenicity score calculated

• Deimmunization strategy proposed

• Clinical precedent comparison

Phase 7: Manufacturing

• Expression system assessed

• Purification strategy outlined

• Formulation recommended

• CMC timeline estimated

Phase 8: Final Report

• Ranked variant list

• Top candidate recommended

• Experimental validation plan

• Backup variants identified

• Next steps outlined

Tool Reference

IMGT Tools

• IMGT_search_genes : Search germline genes (IGHV, IGKV, etc.)

• IMGT_get_sequence : Get germline sequences

• IMGT_get_gene_info : Database information

Antibody Databases

• SAbDab_search_structures : Search antibody structures

• SAbDab_get_structure : Get structure details

• TheraSAbDab_search_therapeutics : Search by name

• TheraSAbDab_search_by_target : Search by target antigen

Immunogenicity

• iedb_search_epitopes : Search epitopes

• iedb_search_bcell : B-cell epitopes

• iedb_search_mhc : MHC-II epitopes

• iedb_get_epitope_references : Citations

Structure & Target

• AlphaFold_get_prediction : Structure prediction

• UniProt_get_protein_by_accession : Target info

• PDB_get_structure : Experimental structures

Systems Biology (for Bispecifics)

• STRING_get_interactions : Protein interactions

• STRING_get_enrichment : Pathway analysis

Special Considerations

Bispecific Antibody Engineering

• Use STRING tools to identify co-expressed targets

• Design separate binding arms for each target

• Consider asymmetric formats (e.g., CrossMAb, DuoBody)

• Assess aggregation risk (higher for bispecifics)

pH-Dependent Binding

• Add His residues at interface (pKa ~6.0)

• Target: Bind at pH 7.4, release at pH 6.0

• Improves PK via FcRn recycling

• Useful for tumor targeting (acidic microenvironment)

Affinity Ceiling

• Most therapeutic antibodies: KD 0.1-10 nM

• <0.1 nM: May cause target-mediated clearance

• 1-5 nM: Sweet spot for most targets

• Balance affinity vs. developability